Human Recombinant CFB protein, His Tag (V2LY-0526-LY3984)

Go to compare Compare Online Inquiry
Request for COA
Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Expressed Host
HEK293 Cells
Protein Species
Human
Tag
His Tag
Protein Construction
This product is Human Recombinant CFB protein, His Tag consist of Amino Acid: 1-764 and predicts a molecular mass of 84.5 kDa.
Molecule Mass
84.5 kDa
Verified
HPLC
Sequence
Amino Acid: 1-764
Species
Human

Formulations & Storage [For reference only, actual COA shall prevail!]

Purity
≥90% as determined by SDS-PAGE. ≥90% as determined by SEC-HPLC.
Endotoxin
Please contact us for more information.
Format
Lyophilized
Reconstitution
Allow the vial and reconstitution buffer to equilibrate to room temperature. Briefly centrifuge or tap down the vial to ensure that all lyophilized powder is collected at the bottom of the vial. For the reconstitution of this product, we recommend adding PBS or sterile water to achieve a final antibody concentration of 1 mg/mL. Allow the vial to reconstitute for 10-15 minutes at room temperature with gentle agitation. Avoid vigorous shaking that can cause foaming and antibody denaturation. Aliquot into volumes based on your experiment and store liquid protein at -20°C or -80°C for long time.
Buffer
Lyophilized from sterile Tirs, NaCl, Glycerol
Preservative
None
Storage
Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
More Infomation

Target

Full Name
Complement Factor B
Function
Factor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb. Bb, a serine protease, then combines with complement factor 3b to generate the C3 or C5 convertase. It has also been implicated in proliferation and differentiation of preactivated B-lymphocytes, rapid spreading of peripheral blood monocytes, stimulation of lymphocyte blastogenesis and lysis of erythrocytes. Ba inhibits the proliferation of preactivated B-lymphocytes.
Biological Process
Complement activation Source: Reactome
Complement activation, alternative pathway Source: Reactome
Regulation of complement activation Source: Reactome
Cellular Location
Secreted
Involvement in disease
Macular degeneration, age-related, 14 (ARMD14): Disease susceptibility may be associated with variants affecting the gene represented in this entry. Haplotype analyses have identified a statistically significant common risk haplotype and two protective haplotypes. CFB variant His-9 and C2 variant Asp-318, as well as CFB variant Gln-32 and a variant in intron 10 of C2, confer a significantly reduced risk of AMD. A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
Hemolytic uremic syndrome atypical 4 (AHUS4): Disease susceptibility is associated with variants affecting the gene represented in this entry. Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease.
Complement factor B deficiency (CFBD): An immunologic disorder characterized by increased susceptibility to bacterial infections, particularly Neisseria infections, due to a defect in the alternative complement pathway.

Lee, M. J., Na, K., Shin, H., Kim, C. Y., Cho, J. Y., Kang, C. M., ... & Paik, Y. K. (2021). Early Diagnostic Ability of Human Complement Factor B in Pancreatic Cancer Is Partly Linked to Its Potential Tumor-Promoting Role. Journal of proteome research, 20(12), 5315-5328.

Lu, Q., Hou, Q., Cao, K., Sun, X., Liang, Y., Gu, M., ... & Dai, C. (2021). Complement factor B in high glucose–induced podocyte injury and diabetic kidney disease. JCI insight, 6(19).

Shimazaki, R., Takano, S., Satoh, M., Takada, M., Miyahara, Y., Sasaki, K., ... & Ohtsuka, M. (2021). Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer. Cellular Oncology, 1-14.

Wang, X., Shang, Q. L., Ma, J. X., Liu, S. X., Wang, C. X., & Ma, C. (2020). Complement factor b knockdown by short hairpin rna inhibits laser-induced choroidal neovascularization in rats. International journal of ophthalmology, 13(3), 382.

Pilotti, C., Greenwood, J., & Moss, S. E. (2020). Functional Evaluation of AMD-Associated Risk Variants of Complement Factor B. Investigative ophthalmology & visual science, 61(5), 19-19.

Chen, H., Sun, J., Zhou, B., Peng, J., Xie, Q., Liang, X., ... & Jiang, J. (2020). A missense variant in complement factor B (CFB) is a potential predictor of 24‐week off‐treatment response to PegIFNα therapy in Chinese HBeAg‐positive chronic hepatitis B patients. Alimentary pharmacology & therapeutics, 51(4), 469-478.

Kim, S. H., Lee, M. J., Hwang, H. K., Lee, S. H., Kim, H., Paik, Y. K., & Kang, C. M. (2019). Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study. Cancer Biomarkers, 24(3), 335-342.

Matsunaga, H., Iwashita, M., Shinjo, T., Yamashita, A., Tsuruta, M., Nagasaka, S., ... & Nishimura, F. (2018). Adipose tissue complement factor B promotes adipocyte maturation. Biochemical and biophysical research communications, 495(1), 740-748.

Coan, P. M., Barrier, M., Alfazema, N., Carter, R. N., Marion de Procé, S., Dopico, X. C., ... & Aitman, T. J. (2017). Complement factor B is a determinant of both metabolic and cardiovascular features of metabolic syndrome. Hypertension, 70(3), 624-633.

Riihilä, P., Nissinen, L., Farshchian, M., Kallajoki, M., Kivisaari, A., Meri, S., ... & Kähäri, V. M. (2017). Complement component C3 and complement factor B promote growth of cutaneous squamous cell carcinoma. The American journal of pathology, 187(5), 1186-1197.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Human Recombinant CFB protein, His Tag?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

online inquiry
Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.